Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

This study has been completed.
Sponsor:
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00180024
First received: September 9, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The hypothesis is tested that stimulation with angiotensin II after blockade of the AT1-receptor results in venodilation in human healthy subjects in vivo.


Condition Intervention
Healthy Subjects
Drug: irbesartan (drug)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training

Resource links provided by NLM:


Further study details as provided by Technische Universität Dresden:

Study Start Date: January 2002
Estimated Study Completion Date: September 2005
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy subjects

Exclusion Criteria:

  • any relevant disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00180024

Locations
Germany
Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Study Chair: Wilhelm Kirch, MD Institute of Clinical Pharmacology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00180024     History of Changes
Other Study ID Numbers: IKPD 01-02
Study First Received: September 9, 2005
Last Updated: September 9, 2005
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Technische Universität Dresden:
AT1-receptor
AT2-receptor
human pharmacology

Additional relevant MeSH terms:
Irbesartan
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 21, 2014